Geron Corp. buy melinda
Start price
03.09.12
/
50%
€2.25
Target price
04.03.13
€2.80
Performance (%)
-51.11%
End price
04.03.13
€1.10
Summary
This prediction ended on 04.03.13 with a price of €1.10. Massive losses of -51.11% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Geron Corp. | -1.031% | -1.031% | -58.445% | -60.913% |
| iShares Core DAX® | -1.432% | 0.000% | 12.331% | 59.631% |
| iShares Nasdaq 100 | -0.386% | -0.595% | 4.688% | 98.396% |
| iShares Nikkei 225® | 1.448% | 5.269% | 18.051% | 50.544% |
| iShares S&P 500 | 0.114% | -0.217% | 1.388% | 63.586% |
Comments by melinda for this prediction
In the thread Geron Corp. diskutieren
pharma
Geron Corp ist ein biopharmazeutisches Unternehmen, das therapeutische Klasse für Krebs entwickelt (Brust, Lunge)
(Laufzeit überschritten)